Scholarlink

<p>Hospital-acquired pneumonia (HAP) is a serious infection with high mortality rates, especially in critically ill patients. The role of corticosteroids as adjunctive therapy in this population is debated. These agents have anti-inflammatory and immunomodulatory properties, which have the potential to reduce pulmonary inflammation and improve oxygenation. However, the risk of secondary infections and metabolic complications that their use may entail is a matter for concern, given their impact on patients’ outcome. In this review, we discuss the current scientific evidence on the use of corticosteroids as adjunctive therapy for patients with HAP and VAP, its implications for patients’ clinical outcomes, and the possible effects. Corticosteroids are not recommended as standard therapy for HAP/VAP but may be beneficial in selected subgroups of patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Corticosteroids and hospital-acquired pneumonia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Lucia Alessandra Pasqua,
  • Catia Cilloniz,
  • Antoni Torres

摘要

Hospital-acquired pneumonia (HAP) is a serious infection with high mortality rates, especially in critically ill patients. The role of corticosteroids as adjunctive therapy in this population is debated. These agents have anti-inflammatory and immunomodulatory properties, which have the potential to reduce pulmonary inflammation and improve oxygenation. However, the risk of secondary infections and metabolic complications that their use may entail is a matter for concern, given their impact on patients’ outcome. In this review, we discuss the current scientific evidence on the use of corticosteroids as adjunctive therapy for patients with HAP and VAP, its implications for patients’ clinical outcomes, and the possible effects. Corticosteroids are not recommended as standard therapy for HAP/VAP but may be beneficial in selected subgroups of patients.